In lat Application No

A. CLASSI	FICATION OF SUBJECT MATTER A61K31/427 A61K31/4192 A61K31/	/4100	A61V31 /A33	ACIDSE /	'nn
IPC 7	A61P31/12 A61P19/02 A61P11/	/4196 /06	A01K31/433 A61P3/10	A61P17/	00
	A61P25/00 A61P25/28 A61P3//	/00			
	nternational Patent Classification (IPC) or to both national classification	fication and	IPC		
	SEARCHED	alla a sumb	ab.)		
Minimum do IPC 7	ocumentation searched (classification system followed by classification sy	ацюп бутю	ois)		
Documental	tion searched other than minimum documentation to the extent tha	at such docu	ments are included in ti	he fields search	ed
Electronic d	ata base consulted during the International search (name of data	base and,	where practical, search t	erms us ed)	
EPO-In	ternal, CHEM ABS Data, BIOSIS, EMB	ASE, W	PI Data, BEIL	STEIN Da	ta
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the	relevant pa	ssages		Relevant to claim No.
Х	WO 01/34580 A (BEIGHT DOUGLAS W MCMILLEN WILLIAM THOMAS (US); L (US);) 17 May 2001 (2001-05-17)	ILLY C	O ELI		1-9, 11-14, 20,22-26
	abstract page 3, line 26 - page 4, line page 23, line 13 - page 31, line 20,28; examples 1-17; table 1 page 6, line 10 - page 7, line	ne 9; c	laims		
х	US 5 869 509 A (GRIBKOFF VALENT AL) 9 February 1999 (1999-02-09	_	ET		1-9, 11-16, 20,22-26
	abstract column 5, line 40 - column 30, examples 11-19,21-38,40-57,61-6 claims 1-14; examples 122,126-1	3,65-1	.20		
		-/			
		•			
X Furt	ther documents are listed in the continuation of box C.	X	Patent family members	are listed in an	nex.
° Special ca	ategories of cited documents:	*T* late	er document published af	ter the Internati	onal filing date
'A' docum	ent defining the general state of the art which is not dered to be of particular relevance	or di	priority date and not in or ted to understand the pri- vention	onflict with the	application but
'E' earlier	document but published on or after the International date	"X" doc	cument of particular releven	rance; the claim	ed invention considered to
'L' docum which	ent which may throw doubts on priority claim(s) or a is cited to establish the publication date of another on or other special reason (as specified)	in 'Y' dod	volve an inventive step w current of particular relevents to in	/hen the docum /ance: the claim	ent is taken alone ed invention
"O" docum	ment referring to an oral disclosure, use, exhibition or means	dk	innot be considered to in ocument is combined with ents, such combination i	h one or more o	ther such docu-
P docum	neans bent published prior to the international filing date but than the priority date claimed	in	the art. cument member of the sa	-	
Date of the	actual completion of the international search	De	te of mailing of the inter	ational search i	eport
2	26 October 2004		08/11/2004		
Name and	mailing address of the ISA	Au	thorized officer		
	European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,		A. Jakobs		

rul/GB2004/002755

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages	левуди (О Сідіні ічо.
X	DE 43 20 801 A (FAHLBERG LIST PHARMA GMBH) 5 January 1995 (1995-01-05) abstract claims 1-3; examples 4,5; tables 1,2	1-9,20, 22-26
X	EP 1 293 503 A (MERCK PATENT GMBH; YAMANOUCHI PHARMA CO LTD (JP)) 19 March 2003 (2003-03-19) abstract page 3, line 41 - page 8, line 32 page 20, line 3 - page 42, line 39; examples 1-288	1-9, 11-16, 20,22-26
X	EP 1 070 708 A (HOFFMANN LA ROCHE) 24 January 2001 (2001-01-24) the whole document	1-9, 11-16, 20,22-26
X	WO 99/64415 A (KATO TOMOKI; PFIZER PHARMA (JP); ANDO KAZUO (JP); KAWAI AKIYOSHI (JP)) 16 December 1999 (1999-12-16) abstract page 3, line 24 - page 4, line 24; claims 1-15; examples 1-198	1-4,7,8, 14-18, 20-26
X	WO 03/015777 A (GIEGRICH KRISTINA; BAUER ULRIKE (DE); DEUSCHLE ULRICH (DE); KOGL MANF) 27 February 2003 (2003-02-27) abstract paragraphs '0014!, '0015!, '0025! - '0033! paragraph '0085!; claims 1-32; tables 3-6	1-3,7-9, 11,12, 14-16, 20,22-26
X	FR 2 258 180 A (CERMOL SA) 18 August 1975 (1975-08-18) the whole document	1,3,8,9, 15,16, 20,22-26
X	GB 1 406 345 A (THIEMANN CHEM PHARM FAB) 17 September 1975 (1975-09-17) the whole document	1-3, 7-10,20, 22-26
X	WO 01/34198 A (BEIGHT DOUGLAS WADE ; MCMILLEN WILLIAM THOMAS (US); TEICHER BEVERLY AN) 17 May 2001 (2001-05-17) the whole document	1-14, 22-26
X	WO 99/40088 A (DIMENSIONAL PHARM INC) 12 August 1999 (1999-08-12) abstract page 5, line 16 - page 6, line 10; example 196	1-3,7-9, 14,15, 20,22-26
	-/	

Ini nal Application No PCI/GB2004/002755

Category °	citation of choument with indication, where appropriete of the relevant passages	Relayant to sleim Ma
ogredion, ,	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	US 5 489 598 A (CONNOR DAVID T ET AL) 6 February 1996 (1996-02-06)	1-9,11, 12, 14-16, 20,22-26
	column 2, lines 5-12; examples 1-61	1 22,22 20
X	WO 01/07436 A (BURNS CHRISTOPHER J ; CHOI SLEDESKI YONG MI (US); LAU WAN F (US); PAUL) 1 February 2001 (2001-02-01) abstract; example 1201 page 395, line 1 - page 397, line 14	1-3,7-9, 15,20, 22-26
X	FEVIG JOHN M ET AL: "Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 5, 12 March 2001 (2001-03-12), pages 641-645, XP002301746 ISSN: 0960-894X the whole document	1-6,8, 11,17, 19,21, 24-26
Ρ,Χ	WO 03/101985 A (AMGEN INC; NGUYEN THOMAS (US); NORMAN MARK H (US); WANG HUI-LING (US)) 11 December 2003 (2003-12-11) abstract page 33, line 1 - page 36, line 27; claims 1,15-39; example 42	1-4,7-9, 14-16, 20,22-26
P, X	WO 03/104207 A (MERCK & CO INC; OLSON STEVEN H (US); ZHU YUPING (US); BALKOVEC JAMES) 18 December 2003 (2003-12-18) abstract page 5, line 16 - page 16, line 21 page 58, line 1 - page 60, line 3; claims 1-29; examples 3-15	1-9,11, 12,15, 16,20, 22-26
P,X	WO 2004/030611 A (GIRARDET JEAN-LUC; HERNANDEZ MARTHA A DE LA ROSA (US); GUNIC ESMIR (U) 15 April 2004 (2004-04-15) abstract page 3, lines 18-28; tables 2,4	1-3,5-9, 11-16, 20,22-26

national application No. PCT/GB2004/002755

INTERNATIONAL SEARCH REPORT

Box il	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This Inte	rnational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claim 22 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
з. 🔲	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This inte	rnational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
з. 🗀	As only some of the required additional search fees were timely paid by the applicant, this international Search Report
	covers only those claims for which fees were paid, specifically claims Nos.:
F	
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest
	No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claim 22 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.:

There are two claims 17 and no claim 20. For the purposes of the search report, the second claim number 17 has been considered as claim number 18, the claim 18 has been considered as claim 19, claim 19 has been considered as claim 20.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

International application No.

INTERNATIONAL SEARCH REPORT

PCT/GB2004/002755

Box No: IV Text of the abstract (Continuation of item 5 of the first sheet)

Compound of a compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity:

wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms, for example a 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R_1 R_2 R_3 are as defined in the specification are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis, angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie /CJD, Huntingdon's and Alzheimer's disease.

II 1al Application No

				rc1/60	2004/002/55
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0134580	A	17-05-2001	AU BR CA CN	1761001 A 0015482 A 2391230 A1 1387518 T	06-06-2001 25-06-2002 17-05-2001 25-12-2002
			EP	1263743 A1	11-12-2002
			JP MV	2003513962 T PA02004646 A	15-04-2003 02-09-2002
			MX WO	0134580 A1	17-05-2001
			ÜS	6797723 B1	28-09-2004
			US	2004198779 A1	07-10-2004
US 5869509	Α	09-02-1999	US	6077861 A	20-06-2000
			US Au	6271249 B1 711736 B2	07-08-2001 21-10-1999
			AU	4067997 A	20-02-1998
			BR	9710793 A	17-08-1999
			CN	1226803 A ,B	25-08-1999
			CZ	9900321 A3	16-06-1999 19-05-1999
			EP Hu	0915856 A1 0000063 A2	29-01-2001
			JP	2000516925 T	19-12-2000
			KR	2000029735 A	25-05-2000
			NO	990428 A	29-01-1999
			NZ	334403 A	29-09-2000
			PL RU	331385 A1 2175319 C2	05-07-1999 27-10-2001
			TW	467902 B	11-12-2001
			WO	9804135 A1	05-02-1998
			ZA	9706554 A	25-01-1999
DE 4320801	A	05-01-1995	DE	4320801 A1	05-01-1995
EP 1293503	Α	19-03-2003	AU	5676901 A	26-11-2001
•			BR CA	0110961 A 2409819 A1	29-06-2004 18-11-2002
			EP	1293503 A1	19-03-2003
			ĤÜ	0302415 A2	28-11-2003
			NO	20025517 A	18-11-2002
			SK	16242002 A3	01-04-2003
			US Cn	2003216385 A1 1429215 T	20-11-2003 09-07-2003
			CZ	20023763 A3	12-03-2003
			WO	0187855 A1	22-11 - 2001
			PL	359340 A1	23-08-2004
				200210245 A	18-03-2004
EP 1070708	Α	24-01-2001	EP AT	1070708 A1 257827 T	24-01-2001 15-01-2004
			AU	773463 B2	27-05-2004
			AU	4865100 A	25-01-2001
			BR	0003075 A	13-03-2001
			CA	2314009 A1	21-01-2001
			CN	1281852 A	31-01-2001
			DE DK	60007697 D1 1070708 T3	19-02-2004 10-05-2004
			ES	2211420 T3	16-07-2004
			HR	20000482 A1	30 - 06-2001

Inti mal Application No PC 17 &B2004/002755

Patent document		Publication date		Patent family member(s)	Publication date
cited in search report	 A	Clate	ID	26599 A	25-01-2001
EP 1070708	A		JP	2001064263 A	13-03-2001
					22-01-2001
			NO	20003723 A	
			NZ	505766 A	28-03-2002
			PL	341616 A1	29-01-2001
			SG	98422 A1	19-09-2003
			TR	200002097 A2	21-02-2001
			ÜS	6265426 B1	24-07-2001
			ZA	200003680 A	22-01-2001
	A	16-12-1999	AT	267196 T	15-06-2004
WO 9904415	^	10-12-1333	AU	3841499 A	30-12-1999
					24-06-2004
			DE	69917451 D1	
			DK	1086097 T3	09-08-2004
			ΕP	1086097 A1	28-03-2001
			WO	9964415 A1	16-12-1999
			JP	2002517496 T	18-06-2002
			PT	1086097 T	31-08-2004
					04-12-2003
			US	2003225064 A1	
			US	2004157824 A1	12-08-2004
			US	2002045654 A1	18 - 04-2002
WO 03015777	A	27-02-2003	EP	1285914 A1	26-02-2003
			WO	03016280 A1	27-02-2003
			EP	1423370 A1	02-06-2004
				1423111 A1	02-06-2004
			EP		
			EP	1423113 A1	02-06-2004
			WO	03016288 A1	27-02-2003
			WO	03015771 A1	27-02-2003
			WO	03015777 A1	27-02-2003
			ÜS	2003187042 A1	02-10-2003
			US	2003149087 A1	07-08-2003
			US	2003130296 A1	10-07-2003
		10_00_1075	CH	577985 A5	30-07-1976
FR 2258180	Α	18-08-1975			24-07-1975
			DE	2460664 A1	
			FΙ	750026 A	22-07-1975
			FR	2258180 A1	18-08-1975
			JP	50101356 A	11-08-1975
GB 1406345	Α	17-09-1975	DE	2250343 A1	18-04-1974
#5 2:1000TO	,,		BE	805838 A1	01-02-1974
			FR	2202692 A1	10-05-1974
			NL	7313957 A ,	
			NL 	7610797 A	31-01-1977
WO 0134198	A	17-05-2001	AU	1916601 A	06-06-2001
			WO	0134198 A2	17-05-2001
WO 9940088	Α	12-08-1999	AT	223408 T	15-09-2002
WU 3340000	V	15 00-1993	ΑÜ	765072 B2	11-09-2003
					23-08-1999
			AU	2666599 A	
			CA	2321025 A1	12-08-1999
			DE	69902754 D1	10-10-2002
			DE	69902754 T2	07-08-2003
			ĒΡ	1054886 Al	29-11-2000
			.10	2002502852 T	29-01-2002
			JP NZ	2002502852 T 506507 A	29-01-2002 29-08-2003

Into nal Application No
PCI/BB2004/002755

					017 002	004/002/33
Patent doc cited in searc		Publication date		Patent family member(s)		Publication date
WO 99400	188 A		US	6562840	B1	13-05-2003
			WO	9940088		12-08-1999
			ÜS	6291514		18-09-2001
			US	2001031781		18-10-2001
US 5489	98 A	06-02-1996	NONE			<u> </u>
WO 01074	36 A	01-02-2001	AU	1923300	A	19-06-2000
			ΑU	773227	B2	20-05-2004
			AU	6462800	Α	13-02-2001
			BG	106340	Α	31-10-2002
			BR	0013179	Α	02-04-2002
			CA	2382755		01-02-2001
			CN	1420882		28-05-2003
			CZ	20020323		15-05-2002
			ĔĒ	200200045		16-06-2003
			ĒΡ	1208097		29-05-2002
			HR	20020076		31-12-2003
		•	HÜ	0203375		28-12-2002
			WO	0107436		01-02-2001
			JP	2003529531		07-10-2003
			JP	2003508353	†	04-03-2003
			MX	PA02000888		30-07-2002
		•	NO	20020214		02-04-2002
				354998		22-03-2004
		•	PL			
			SK	1182002		06-11-2002
			TR	200200225		21-06-2002
			WO	0032590		08-06-2000
			US	2004102450		27-05-2004
حب نت سربيبوت			ZA	200200543	Α	23-06-2003
WO 0310	.985 A	11-12-2003		2003229068		11-12-2003
			WO	03101985	A1	11-12-2003
WO 03104	207 A	18-12-2003	WO	03104208		18-12-2003
			WO	03104207		18-12-2003
			US	2004048912	A1	11-03-2004
			US	2004106664	A1	03-06-2004
			0.5	2007100004		